Senses Disorder TRIZ Cases

N-substituted phthalamic acid derivatives block Sortilin-mediated interactions to alleviate neurodegenerative and inflammatory processes.

Bicyclic pyridone lactam compounds selectively inhibit RIP1 kinase to address insufficient specificity and efficacy of existing necrostatins.

A segmented intraocular scaffold provides sustained drug delivery to the retina, eliminating repeated injections and patient discomfort.

Urea derivatives achieve selective GSK-3β inhibition to treat neurodegenerative diseases, resolving isoform selectivity trade-offs.

Substituted amide derivatives inhibit Rho kinase activity, providing effective treatment for patients with resistant hypertension.

A polymerizable drug release membrane forms directly over a coated drug core during device body molding.

Segmented porous membranes maintain stable drug concentrations in the eye, eliminating painful bolus injections and infection risks.

Ester protecting groups modify flavonoids to enhance solubility and pharmacokinetic properties, treating ischemia and reperfusion injuries.

C20-D3-retinal substrates impede A2E accumulation without delaying dark adaptation, avoiding adverse visual effects.

A topical formulation combining astaxanthin, resveratrol, pyruvate, and EGCG in a carbomer gel reduces oxidative stress to delay cataracts.

Pyrimidine derivatives block VEGF signaling pathways, reducing pathological neovascularization and vascular leakage in ocular disorders.

Modified LCAT enzyme increases HDL cholesterol levels to prevent arterial wall accumulation, addressing low HDL limitations in atherosclerosis treatment.

Novel multifunctional radical quenchers increase ATP concentration in CoQ10 deficient cells through targeted electron donation mechanisms.

PEDF restores choriocapillaris health and visual acuity while avoiding cardiovascular risks from anti-VEGF therapies.

A composition combining alginate with a proton pump inhibitor targets inner ear dysfunction through biochemical modulation.

Substituted pyrrole amides antagonize alpha v integrin pathways, addressing unmet medical needs in fibrosis and cancer treatment.

Adeno-associated virus vectors deliver therapeutic genes to create permanent tissue depots, eliminating repeated injections and reducing immunogenicity.

(-)-2-sec-butyl-6-isopropylphenol delivers potent anesthesia via GABA A receptor activation.

Substituted amide derivatives inhibit Rho kinase activity, addressing medication resistance in cardiovascular and neurological disorders.

Recombinant AAV2 vectors transduce primary cilia in renal and retinal cells to deliver corrective transgenes.

Heteroaryl acoramidis analogs cross the blood-brain barrier to halt ocular and cerebral amyloid deposition where standard treatments fail.

Micellar structures solubilize lipophilic drugs in aqueous media, eliminating adverse reactions from oily solvents and simplifying formulation complexity.

3-aryl-5-substituted-isoquinolin-1-one compounds inhibit PARP enzymes and Wnt signaling pathways.

Formula I heterocyclic compounds block IL-12 synthesis to reduce excessive TH1 inflammatory responses in autoimmune disorders.

Substituted benzofused derivatives modulate vanilloid receptors to alleviate acute and chronic pain states.

Spiroheterobenzazepine compounds block V1a and V2 receptors, resolving selectivity trade-offs in hypertension treatment.

Tetanus toxin expression cleaves VAMP2 proteins in donor photoreceptors to enhance intracellular material transfer via nanotubes.

A method producing autologous serum eye drops from patient blood using centrifugal separation and controlled filling.

Nanonized drug particles overcome anatomical barriers to improve ocular bioavailability without toxic co-solvents.

TrkB agonist antibodies bypass BDNF instability and p75NTR toxicity to treat neurodegeneration.

Substituted pyridazine derivatives block viral adhesion and uncoating on the capsid protein VP1, reducing toxicity compared to existing antiviral agents.

Amino acid substitutions in disintegrin variants reduce binding to alphaIIbbeta3 integrin, mitigating bleeding risks while maintaining anti-angiogenic efficacy.

MitoQ targets mitochondrial complex I to reduce oxidative damage while preserving cellular signaling and oxidative phosphorylation.

Cyclohexane derivatives modulate the PGI2 receptor to replace continuous intravenous infusion with stable oral formulations.

Fluoro-9-methyl-beta-carbolines overcome biologic membrane barriers by increasing lipophilicity, improving inner ear delivery while reducing toxicity.

A recombinant nucleic acid uses a mitochondrial targeting sequence to deliver therapeutic genes via adeno-associated virus vectors.

Administering JAK inhibitors prevents hair cell death caused by antibiotics, replacing mechanical hearing aids with biochemical repair.

Engineered yeast host cells overexpress Kex2p, Pdi1, and Ero1 to enhance recombinant polypeptide secretion.

Nitrogen-containing spiro-ring compounds selectively inhibit JAK3 and JAK2 kinases, resolving limited treatment options for organ transplant rejection.

A dermal composition uses 2-O-α-D-glucosyl-L-ascorbic acid to enhance skin turnover and inhibit glycation.

A biodegradable intraocular implant delivers sustained prostamide release through a specialized polymer matrix.

Preimplantation factor peptide induces immune tolerance by selectively modulating cytokine profiles and cellular responses.

Prime editing corrects PRPH2 splice site mutations via Cas9 nickase and reverse transcriptase, restoring canonical mRNA splicing.

Novel CaMKII inhibitors target cardiac enzyme activity, resolving insufficient symptom control in existing therapies.

A hydrophilic polymer implant with Vitamin E TPGS maintains steady-state octreotide levels, reducing injection frequency for acromegaly treatment.

A 4,5-resolvin conjugate accelerates tissue regeneration through active inflammation resolution.

Small molecule compounds replace peptides to improve oral absorbability and blood-brain barrier permeability for melanocortin receptor activation.

Engineered rAAV capsid proteins target ocular tissues, resolving limited tropism in existing vectors.

A lacrimal implant system delivers anti-glaucoma medications via a polymer matrix for controlled drug release.